Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 11/20 | 0.63 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606108 | 1.00 | ERBB2 (0.63) | ERBB2MINK1MMP1MMP2MMP9 | |
| SCHEMBL5649779 | 0.89 | ERBB2 (0.59) | ERBB2MINK1 | |
| SCHEMBL27652951 | 0.89 | ERBB2 (0.59) | ERBB2MINK1 | |
| SCHEMBL5045125 | 0.89 | ERBB2 (0.59) | ERBB2MINK1 | |
| SCHEMBL5045124 | 0.89 | ERBB2 (0.59) | ERBB2MINK1 | |
| SCHEMBL4607047 | 0.88 | ERBB2 (0.53) | ERBB2MINK1 | |
| SCHEMBL4607046 | 0.88 | ERBB2 (0.53) | ERBB2MINK1 | |
| SCHEMBL5524354 | 0.85 | ERBB2 (0.85) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5043377 | 0.85 | ERBB2 (0.67) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5043378 | 0.85 | ERBB2 (0.67) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | claimed |
| EP-1761525-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | claimed |
| WO-2005116019-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | claimed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | claimed |
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1761525-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005116019-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | TPMT, TST, SULT1E1 | ERBB2 581/4885MINK1 2814/4885MMP1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.